Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SG1906 in CLDN18.2-Positive Solid Tumors
NCT05857332Phase 1Recruiting
- Sponsor
- Shangjian Bio
- Start
- May 2023
- Primary completion
- Feb 2027
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SG1906 in solid tumor, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and 1 more, sponsored by Shangjian Bio. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 1 year and Maximum Tolerated Dose / Maximum Administered Dose / Recommended Phase 2 Dose at 1 year. Started May 2023; status: recruiting.
02
Drugs
SG1906
03
Conditions
solid tumorgastric adenocarcinomagastroesophageal junction adenocarcinomapancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05857332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05857332.